BETHESDA, Md.--(BUSINESS WIRE)--Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP), an international pharmaceutical company, today announced that its Board of Directors has approved the repurchase of up to an aggregate of $2,000,000 of its Class A common stock out of the $10,000,000 authorized by the Board on December 9, 2008. At that time, the Board authorized a stock repurchase program in which the Company may use up to $10,000,000 to purchase shares of its Class A common stock.
